Daratumumab, lenalidomide, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma: A real-world propensity score-matched study. - Lin CH; Liao PW; Teng CJ; Su YC; Chen TC; Yang SF; Ko BS (Journal of the Formosan Medical Association = Taiwan yi zhi, 2026)